Good morning, everybody, and welcome to a different working week. We hope the weekend respite was enjoyable and invigorating, as a result of that oh-so-familiar routine of conferences, deadlines, and messages has returned. However what are you able to do? There isn’t any pause button to cease the world from spinning. So this implies one factor: time to dig in to the duties at hand. On that notice, we’ve got assembled a menu of tidbits that will help you get began. In the meantime, we’ve got additionally fired up the espresso kettle for an additional cup of stimulation. Our selection at this time is banana break up. We hope your day is solely smashing and, as at all times, do communicate if one thing juicy arises. …
President Trump stated Sunday that he would signal an government order to base U.S. drug costs on what different nations pay — often far lower than Individuals do, STAT says. The order, which was extensively anticipated, will imply the U.S. will “pay the identical worth because the Nation that pays the bottom worth wherever within the World,” Trump wrote in a Reality Social submit. However the assertion left unanswered key questions concerning the so-called “most-favored nation” coverage — which Trump additionally tried to advance in his first administration — and any effort is sort of sure to be challenged by the pharmaceutical trade in courtroom. Trump stated the order, which he plans to signal Monday morning, would lower drug costs “virtually instantly, by 30% to 80%,” and would save trillions for the U.S. He referred to as the coverage “probably the most consequential Government Orders in our Nation’s historical past.” Nevertheless it is probably not that easy. When the same coverage was proposed in Trump’s first time period, it was blocked by the courts, although the president’s supporters say he can keep away from the same defeat this time by extra rigorously adhering to policymaking guidelines for the manager department.
Eli Lilly disclosed that its Zepbound drug was superior to Novo Nordisk’s Wegovy throughout 5 weight-loss targets comparable to decreasing waist circumference, citing information from a head-to-head trial, Reuters notes. The info are from the primary head-to-head trial evaluating the wildly standard medicines, and provides Lilly extra firepower because it seeks to realize wider insurance coverage protection in an weight problems drug market estimated to succeed in greater than $150 billion yearly by the subsequent decade. Zepbound helped practically 25% extra individuals lose greater than 15% of their weight in comparison with Wegovy, in response to Lilly. The trial additionally confirmed that remedy with Zepbound achieved a superior common waist circumference discount of 18.4 centimeters, whereas these handled with Wegovy noticed a median discount of 13 centimeters. Novo Nordisk countered that the load loss for Wegovy within the head-to-head trial was decrease than in a 2021 trial with the same dose.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
